179 related articles for article (PubMed ID: 37855644)
1. Severe Cushing's syndrome from an ectopic adrenocorticotropic hormone-secreting neuroendocrine tumour treated by osilodrostat.
Hána V; Brutvan T; Krausová A; Kršek M; Hána V
Endocrinol Diabetes Metab Case Rep; 2023 Oct; 2023(4):. PubMed ID: 37855644
[TBL] [Abstract][Full Text] [Related]
2. Approach to the Patient Treated with Steroidogenesis Inhibitors.
Castinetti F; Nieman LK; Reincke M; Newell-Price J
J Clin Endocrinol Metab; 2021 Jun; 106(7):2114-2123. PubMed ID: 33675650
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
[TBL] [Abstract][Full Text] [Related]
4. Adrenal Cushing's Syndrome Treated With Preoperative Osilodrostat and Adrenalectomy.
Malik RB; Ben-Shlomo A
AACE Clin Case Rep; 2022; 8(6):267-270. PubMed ID: 36447826
[TBL] [Abstract][Full Text] [Related]
5. Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.
Perosevic M; Tritos NA
Drug Des Devel Ther; 2023; 17():1303-1312. PubMed ID: 37143705
[TBL] [Abstract][Full Text] [Related]
6. Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study.
Detomas M; Altieri B; Deutschbein T; Fassnacht M; Dischinger U
Front Endocrinol (Lausanne); 2022; 13():903545. PubMed ID: 35769081
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples.
Fleseriu M; Biller BMK
Pituitary; 2022 Dec; 25(6):795-809. PubMed ID: 36002784
[TBL] [Abstract][Full Text] [Related]
8. Osilodrostat in Cushing's disease: the management of its efficacy and the pitfalls of post-surgical results.
Antonini S; Brunetti A; Zampetti B; Boeris D; Saladino A; Cesare Cozzi R
Endocrinol Diabetes Metab Case Rep; 2022 Nov; 2022():. PubMed ID: 36515363
[TBL] [Abstract][Full Text] [Related]
9. Cushing's disease: adrenal steroidogenesis inhibitors.
Pivonello R; Simeoli C; Di Paola N; Colao A
Pituitary; 2022 Oct; 25(5):726-732. PubMed ID: 36036308
[TBL] [Abstract][Full Text] [Related]
10. A unique case of ectopic Cushing's syndrome from a thymic neuroendocrine carcinoma.
Lawrence L; Zhang P; Choi H; Ahmad U; Arrossi V; Purysko A; Makin V
Endocrinol Diabetes Metab Case Rep; 2019 Feb; 2019():. PubMed ID: 30802210
[TBL] [Abstract][Full Text] [Related]
11. Classic and recent etiologies of Cushing's syndrome: diagnosis and therapy.
Beauregard C; Dickstein G; Lacroix A
Treat Endocrinol; 2002; 1(2):79-94. PubMed ID: 15765624
[TBL] [Abstract][Full Text] [Related]
12. Median 10 years follow-up of patients with covert Cushing's syndrome: a case series.
Najafipour F; Bahrami A; Niafar M; Houshyar J; Halimi M; Sadra V
J Med Case Rep; 2021 Oct; 15(1):514. PubMed ID: 34635153
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous adrenocorticotropic hormone (ACTH) normalisation due to tumour regression induced by metyrapone in a patient with ectopic ACTH syndrome: case report and literature review.
Iwayama H; Hirase S; Nomura Y; Ito T; Morita H; Otake K; Okumura A; Takagi J
BMC Endocr Disord; 2018 Mar; 18(1):19. PubMed ID: 29587720
[TBL] [Abstract][Full Text] [Related]
14. Synergistic cortisol suppression by ketoconazole-osilodrostat combination therapy.
Amodru V; Brue T; Castinetti F
Endocrinol Diabetes Metab Case Rep; 2021 Dec; 2021():. PubMed ID: 34877930
[TBL] [Abstract][Full Text] [Related]
15. Cushing's Syndrome in Adenocarcinoma of Lung Responding to Osilodrostat.
Heleno CT; Hong SPD; Cho HG; Kim MJ; Park Y; Chae YK
Case Rep Oncol; 2023; 16(1):124-128. PubMed ID: 36876215
[TBL] [Abstract][Full Text] [Related]
16. Differences in the spectrum of steroidogenic enzyme inhibition between Osilodrostat and Metyrapone in ACTH-dependent Cushing syndrome patients.
Bonnet-Serrano F; Poirier J; Vaczlavik A; Laguillier-Morizot C; Blanchet B; Baron S; Guignat L; Bessiene L; Bricaire L; Groussin L; Assié G; Guibourdenche J; Bertherat J
Eur J Endocrinol; 2022 Aug; 187(2):315-322. PubMed ID: 35699971
[TBL] [Abstract][Full Text] [Related]
17. Osilodrostat - an emerging drug for the medical management of Cushing's disease.
Witek P; Mehlich A; Stasiewicz A; Jawiarczyk-Przybyłowska A; Bolanowski M
Endokrynol Pol; 2022; 73(2):371-374. PubMed ID: 35381096
[TBL] [Abstract][Full Text] [Related]
18. PRKAR1A-negative familial Cushing's syndrome: two case reports.
Lim LL; Kitan N; Paramasivam SS; Ratnasingam J; Ibrahim L; Chan SP; Tan AT; Vethakkan SR
J Med Case Rep; 2015 Dec; 9():277. PubMed ID: 26619967
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.
Tanaka T; Satoh F; Ujihara M; Midorikawa S; Kaneko T; Takeda T; Suzuki A; Sato M; Shimatsu A
Endocr J; 2020 Aug; 67(8):841-852. PubMed ID: 32378529
[TBL] [Abstract][Full Text] [Related]
20. Osilodrostat: A Novel Steroidogenesis Inhibitor to Treat Cushing's Disease.
Dougherty JA; Desai DS; Herrera JB
Ann Pharmacother; 2021 Aug; 55(8):1050-1060. PubMed ID: 33143437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
